Does Nifuroxazide Enhance the Effect of Metronidazole Oral Administration in the Treatment of Clostridium difficile Infection?

Abstract

Aims: To evaluate the efficacy of metronidazole monotherapy and modified therapy with metronidazole + nifuroxazidefor the for treatment of a mild form of Clostridium difficile infection (CDI).
 Study Design: A prospective, randomized, controlled clinical trial.
 Place and Duration of Study: University of Applied Sciences Tuzla in the period from June 2018 to June 2019.
 Methodology: Sixty patients were included in the study, divided into two groups. One group received standard therapy (metronidazole) for the treatment of a mild form of CDI, while the other group was treated with modified therapy (metronidazole + nifuroxazide). Subjects with a developed clinical picture and a positive toxin test for Clostridium difficile were surveyed on the day of admission, then on the 4th, 10th, 14th and 30th days from the start of therapy. The goal of the research was to determine the impact of the modified therapy protocol on the number of stools and the presence of pain compared to standard therapy.
 Results: The modified therapy with metronidazole + nifuroxazide showed better pharmacological efficacy in the treatment of CDI compared to the standard therapy with metronidazole alone. The group of subjects who were treated with modified therapy reported a significantly lower number of stools (P=.001) and the absence of pain at the first and second check-ups.
 Conclusion: Nifuroxazide and metronidazole represent a combination of drugs that reduce the number of stools in the shortest possible time and result in the absence of abdominal pain in patients diagnosed with a mild form of CDI.

White sustainable luminescent determination of nifuroxazide using nitrogen–sulphur co-doped carbon quantum dots nanosensor in bulk and various pharmaceutical matrices

“…Such medications include clarithromycin which is indicated for the treatment of H. pylori infection 4 and metronidazole which is used to enhance NFX antibacterial effect. 50 It was found that both tested medications have no effect on NSC-dots luminescence intensity and thus they did not interfere with NFX uorimetric analysis. Additionally, the good percentage recoveries presented in Table 3 demonstrate that the excipients and additives co-formulated within the pharmaceutical formulations did not affect the proposed luminescent methodology.…”